Aslan Pharmaceuticals Ltd
NASDAQ:ASLN
Intrinsic Value
Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. [ Read More ]
The intrinsic value of one
ASLN
stock under the Base Case scenario is
4.189
USD.
Compared to the current market price of 0.448 USD,
Aslan Pharmaceuticals Ltd
is
Undervalued by 89%.
Aslan Pharmaceuticals Ltd's market capitalization is 10.1m USD.
ASLN stock price is 0.448 USD.
ASLN stock price (0.448 USD) is 89% less than its Intrinsic Value (4.189 USD).
ASLN. Open DCF Valuation
ASLN stock price (0.448 USD) is 89% less than its Relative Value (4.189 USD). Open Relative Valuation
ASLN.
ASLN's long-term liabilties (46m USD) exceed its long-term assets (45m USD).
ASLN has positive three-year average ROIC (Return on Invested Capital): 13%. The company is efficient at using invested capital to generate operating income.
ASLN has positive Gross Profit for the last twelve months.
ASLN's ROE (Return on Equity) has significantly decreased in the last 3 years from -52% to -73%, and is approaching profitability.
ASLN's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 4 995% to 343%.
ASLN has negative Net Debt. This means that the company has more cash and short-term investments (41m USD) than debt (25m USD).
ASLN's short-term assets (44m USD) exceed its short-term liabilties (21m USD).
ASLN has negative Operating Income for the last twelve months.
ASLN has negative Net Income for the last twelve months.
ASLN's ROE (Return on Equity) for the past 12 months is negative and is equal to -73%.
ASLN's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 343%.
ASLN has negative Free Cash Flow for the last twelve months.
ASLN has negative three-year average ROE (Return on Equity): -832%. The company is not efficient at transforming stockholders' equity into net income.
ASLN's D/E (Debt to Equity) is very low and is equal to -27.83.
ASLN's Altman Z-Score is very low and is equal to -10.28.
ASLN doesn't generate enough operating income (-13m USD) to safely cover interest payments on its debt (613k USD).
Valuation Backtest
Aslan Pharmaceuticals Ltd
Run backtest to discover the historical profit from buying and selling
ASLN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Aslan Pharmaceuticals Ltd
Balance Sheet Decomposition
Aslan Pharmaceuticals Ltd
| Current Assets | 44.3m |
| Cash & Short-Term Investments | 40.8m |
| Other Current Assets | 3.5m |
| Non-Current Assets | 343.1k |
| PP&E | 340.4k |
| Intangibles | 2.8k |
| Other Non-Current Assets | -10 |
| Current Liabilities | 21m |
| Accounts Payable | 4.4m |
| Other Current Liabilities | 16.6m |
| Non-Current Liabilities | 24.5m |
| Long-Term Debt | 24.5m |
Earnings Waterfall
Aslan Pharmaceuticals Ltd
|
Revenue
|
12m
USD
|
|
Cost of Revenue
|
0
USD
|
|
Gross Profit
|
12m
USD
|
|
Operating Expenses
|
-24.8m
USD
|
|
Operating Income
|
-12.8m
USD
|
|
Other Expenses
|
1.2m
USD
|
|
Net Income
|
-11.6m
USD
|
Free Cash Flow Analysis
Aslan Pharmaceuticals Ltd
ASLN Profitability Score
Profitability Due Diligence
Aslan Pharmaceuticals Ltd's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Aslan Pharmaceuticals Ltd's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
ASLN Solvency Score
Solvency Due Diligence
Aslan Pharmaceuticals Ltd's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
Aslan Pharmaceuticals Ltd's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ASLN Price Targets Summary
Aslan Pharmaceuticals Ltd
Shareholder Return
ASLN Price
Aslan Pharmaceuticals Ltd
| Average Annual Return | -38.91% |
| Standard Deviation of Annual Returns | 24% |
| Max Drawdown | -99% |
| Market Capitalization | 10.1m USD |
| Shares Outstanding | 22 626 800 |
| Percentage of Shares Shorted | 0.52% |
Company Profile
Aslan Pharmaceuticals Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. The company employs 18 full-time employees The company went IPO on 2017-06-01. The firm is engaged in developing treatments to transform the lives of patients. The firm is focused developing ASLAN004, an antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, an oral inhibitor of dihydroorotate dehydrogenase (DHODH), which is being developed for autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore, and conducts clinical development programs globally.
Contact
IPO
Employees
Officers
The intrinsic value of one
ASLN
stock under the Base Case scenario is
4.189
USD.
Compared to the current market price of 0.448 USD,
Aslan Pharmaceuticals Ltd
is
Undervalued by 89%.
You don't have any saved screeners yet
